{"nctId":"NCT00719680","briefTitle":"Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)","startDateStruct":{"date":"2008-06"},"conditions":["Primary Immune Deficiency"],"count":21,"armGroups":[{"label":"IgPro20","type":"EXPERIMENTAL","interventionNames":["Biological: IgPro20"]}],"interventions":[{"name":"IgPro20","otherNames":["IgG with Proline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with primary humoral immunodeficiency who have participated in the study ZLB04\\_009CR (NCT00419341), namely with a diagnosis of Common Variable Immunodeficiency (CVID) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or X-linked Agammaglobulinemia (XLA) as defined by PAGID and ESID\n* Women of childbearing potential must be using and agree to continue using medically approved contraception and must have a negative pregnancy test at screening\n* Written informed consent\n\nExclusion Criteria:\n\n* Ongoing serious bacterial infection at the time of screening\n* Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma, and immunodeficiency with thymoma\n* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined by total urine protein concentration \\> 0.2 g/L)\n* Other significant medical conditions that could increase the risk to the patient\n* Females who are pregnant, breast-feeding or planning a pregnancy during the course of the study\n* A positive result at screening on any of the following viral markers: Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV)\n* Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration \\> 2.5 times Upper Normal Limit (UNL) at Completion Visit of study ZLB04\\_009CR (NCT00419341)\n* Creatinine concentration \\> 1.5 times UNL at Completion Visit of study ZLB04\\_009CR (NCT00419341)\n* Participation in a study with an investigational product other than IgPro20 within 3 months prior to enrollment\n* Evidence of uncooperative attitude\n* Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial\n* Subjects who are employees at the investigational site, relatives or spouse of the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)","description":"The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.\n\nAcute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Any Infection","description":"The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":null}]}]}]},{"type":"PRIMARY","title":"Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)","description":"The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.\n\nAcute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations","description":"Mean of individual median total IgG trough concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.98","spread":"3.65"}]}]}]},{"type":"SECONDARY","title":"Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"13.49"}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection","description":"The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Hospitalization Due to Infection","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.857","spread":"2.726"}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Hospitalization Due to Infection","description":"The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":null}]}]}]},{"type":"SECONDARY","title":"Use of Antibiotics for Infection Prophylaxis and Treatment","description":"Annualized rate of days with antibiotics for infection prophylaxis and treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of All AEs by Relatedness and Severity","description":"The rate of AEs was the number of AEs over the number of infusions administered.\n\nAt least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.\n\nMild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.661","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.137","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.524","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.575","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.076","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.010","spread":null}]}]}]},{"type":"SECONDARY","title":"Relatedness and Severity of All AEs (Percentage of Total AEs)","description":"At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.\n\nMild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion","description":"AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion","description":"The rate of AEs was the number of AEs over the number of infusions administered.\n\nAEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.322","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.575","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Mild, Moderate, or Severe Local AEs","description":"In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction.\n\nMild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs","description":"Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters","description":"Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers","description":"Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":21},"commonTop":["Sinusitis","Injection site reaction","Infusion site reaction","Nasopharyngitis","Oropharyngeal pain"]}}}